Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6P1J9
UPID:
CDC73_HUMAN
Alternative names:
Cell division cycle protein 73 homolog; Hyperparathyroidism 2 protein
Alternative UPACC:
Q6P1J9; A6NLZ8; B2RBR2; Q6PK51; Q96A07; Q9H245; Q9H5L7
Background:
Parafibromin, known as Cell division cycle protein 73 homolog and Hyperparathyroidism 2 protein, plays a pivotal role in transcriptional and post-transcriptional control pathways. It is crucial in cell cycle progression, embryonic stem cell pluripotency, and hematopoiesis, influencing the expression of cyclin D1/PRAD1 and the transcription of Hox and Wnt target genes.
Therapeutic significance:
Parafibromin's involvement in diseases such as Hyperparathyroidism 1, Hyperparathyroidism 2 with jaw tumors, and Parathyroid carcinoma highlights its potential as a target for therapeutic intervention. Understanding its role could lead to novel treatments for these conditions.